Diagnostyka i leczenie hipercholesterolemii

• Autorzy: Cybulska B , Klosiewicz-Latoszek L.

Warianty tytułu

EN

Diagnosis and treatment of hypercholesterolemia

• Języki publikacji: PL

Słowa kluczowe

PL

zagrozenia zdrowia; choroby czlowieka; dieta; leczenie; diagnostyka; hipercholesterolemia

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2005
• Tom: 32
• Numer: 2
• Strony: 74-92
• Opis fizyczny: s.74-92,rys.,tab.,bibliogr.

Twórcy

autor

Cybulska B

• Instytut Zywnosci i Zywienia, Warszawa

autor

Klosiewicz-Latoszek L.

Bibliografia

• 1. ACC/AHA 2002 guideline uptake for management of patients with chronic stable angina- summary article. J. Am. Coll. Cardiol., 2003, 41, 159-168.
• 2. ACC/ AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article. J. Am. Coll. Cardiol., 2002, 40, 1366-1374.
• 3. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001, 104, 1577-1579
• 4. Anderson J.W., Hanna T.J.: Impact of nondige- stible carbohydrates on serum lipoproteins and risk for cardiovascular disease. J. Nutr., 1999, 129, 1, 457S-1466S.
• 5. Aronow H.D., Topol E.J., Roe M.T., i wsp.: Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357, 1063-1068.
• 6. Bays H.E., Moore P.B., Drehobl M.A., i wsp.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Intern. Peer Rev. J. Drug Therapy 2001, 23, 1209-1229.
• 7. Beynen A.C., Katan M.B.: Reproducibility of the variations between humans in the response of serum cholesterol to cessation of egg consumption. Atherosclerosis 1985, 57, 19-31.
• 8. Bolego C., Baetta R., Bellosta S., i wsp.: Safety considerations for statins. Curr. Opi. Lipidol., 2002, 13, 637-644.
• 9. Cannon C.P., Braunwald E., McCale C.H., i wsp.: Pravastatin or Atorvastatin Evaluation and Ifection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lovering with statins after acute coronary syndromes. N. Engl. J. Med., 2004, 350, 1495-1504.
• 10. Chen Z., et al.: Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentration. Brit. Med. J., 1991, 303, 276-282.
• 11. Clarke R., et al.: Dietary lipids and blood cholesterol: quantative meta-analysis of metabolic ward. Brit. Med. J., 1997, 314, 112-117.
• 12. Colhoun H.M., Betteridge D.J., Durvington PN., i wsp.: Primary prevention of cardiavascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): mulbicentre randomised placebo-countrolled trial. Lancet, 2004, 364, 685-696.
• 13. Comparato C., et al.: Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction. Nutr. Metab. Cardiovasc. Dis., 2001, 11, 328-343.
• 14. Connor W.F., Connor S.L.: Dietary cholesterol and coronary heart disease. Curr. Atherosclerosis Rep., 2002, 4, 425-432.
• 15. Corsini A., et al.: New insights into pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther., 1999, 84, 413-428.
• 16. Dattilo A.M., Kris-Etherton PM.: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr., 1992, 56, 320-328.
• 17. Downs J.R., et al.: for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J. Am. Med. Assoc., 1998, 279, 1615-1622.
• 18. Drevon Ch.A.: n-6 and n-3 fatty acids - how much and which balance? Naringsforsking, 1999, 34, 56-61.
• 19. GISSI - Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of GISSI - Prevenzione Trial. Lancet, 1999, 354, 447-455.
• 20. Goldstein J.L., Brown M.S.: Familial hypercholesterolemia. W: The metabolic basis of inherited disorders. Pod red.: Scriver C.R., Beaudet A.L., Sly W.S., Valle D.: New York McGraw-Hill, 1995, 1981-2030.
• 21. Grundy S.M.: Dietary fats and sterols. In: Nutrition and killer diseases. Ed. D. Kritkchevsky. New York, Wiley, 1981, 57, 83.
• 22. Haffner S.M., et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339, 229- 234.
• 23. Hallikainen M.A., Uusitupa M.I.: Effects of 2 low fat stanol ester-containing magarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Am. J. Clin. Nutr., 1999, 69, 403-410.
• 24. Hamilton-Craig U.: Statin-associated myopathy. Med. J. Aust., 2001, 175, 486-489.
• 25. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20.535 high - risk individuals: a randomized placebo - controlled trial. Lancet 2002, 360, 23-33.
• 26. Innerarity J.L., et al.: Familial defective apolipoprotein B100: a mutatian of apolipoprotein B that causes hypercholesterolemia. J.Lipid. Res., 1990, 31, 1337-1349.
• 27. Jones P., et al.: for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am. J. Cardiol., 1998, 81, 582-587.
• 28. Keys A., et al.: Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge. M.A.: Harvard University Press, 1980, 381.
• 29. Kris-Etherton P.M., et al.: for the AHA Nutrition Committee. Omega-3 fatty acids and cardiovascular disease. Arterioscler. Thromb. Vase. Biol., 2003, 23, 151-152.
• 30. La Rosa J.C., Grundy S.M., Waters D.D., i wsp.: for the Treating to New Targets (TNT) Investigators Intensive lipid lovering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med., 2005, 352, 1425-1435.
• 31. Liem A., et al.: Fluvastatin in acute myocardial infarction: effects on early and late ischemia and events: the FLORIDA trial (abstract). Circulation, 2000, 102, 2672.
• 32. de Logeril M., et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular compliccations after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99, 779-785.
• 33. Lovastatin Study Group I through IV. Lovastatin 5-year safety and efficacy study. Arch. Intern. Med., 1993, 153, 1079-1084.
• 34. McKeown B., Thompson PL.: Early statin therapy after a coronary event. Curr. Opi. Lipidol., 2002, 13, 631-635.
• 35. Mensink R.P., Katan M.B.: Effect of trans fatty acids on high density and low density lipoprotein cholesterol levels in healthy subjects. N. Engl. J. Med., 1990, 323, 439-445.
• 36. Mensink R.P, et al.: Effects of dietary cis and trans fatty acids on serum lipoprotein(a) levels in human. J. Lipid. Res., 1992, 33, 1493-1501.
• 37. Mensink R.P, Katan M.B.: Effects of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. Arterioscler. Thromb., 1992, 12, 911-9.
• 38. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo - controlled trial. Lancet 2002, 360, 7-22.
• 39. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Executive Summary, 1998.
• 40. Newby L.K., et al.: Early statin initiation and outcomes in patients with acute coronary syndroms. J. Am. Med. Assoc., 2002, 287, 3087-3095.
• 41. Ordovas J.M., et al.: Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG reductase inhibitor therapy. Atherosclerosis, 1995, 113, 157-172.
• 42. Pasternak R.C., et al.: ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation, 2002, 106, 1024-1028.
• 43. Phillips PS., et al.: Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med., 2002, 137, 581-585.
• 44. Prevention of cardiovascular events and deaths with pravastatin in patient with coronary heart disease and a broad range of cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N. Engl. J. Med., 1998, 339, 1349-1357.
• 45. Rekomendacje Komisji Profilaktyki Polskiego Towarzystwa Kardiologićznego „Profilaktyka Choroby Niedokrwiennej Serca w Praktyce Klinicznej". Kardiol. Pol., 2000, 53, supl.I, I-5-I-45.
• 46. Roden D.M., George A.L.: The genetic basis of variability in drug responses. Nat. Rev., 2002, 1, 37-44.
• 47. Rosenson R.S., Brown A.S.: Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr. Opi. Lipidol., 2002, 13, 625-630.
• 48. Sack F.M., et al.: For the Cholesterol and Reccurent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 1996, 335, 1001-1009.
• 49. Sever P.S., et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003, 361, 1149-1158.
• 50. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383- 1389.
• 51. Scheafer E.J.: Lipoproteins, nutrition and heart disease. Am. J. Clin. Nutr., 2002, 75, 191-212.
• 52. Schiele R., et al.: Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of MITRA-2. Circulation 2000, 102, 11-435, Abstract 2117.
• 53. Schwartz G.G., Olsson A.G., Ezekowitz M.D., i wsp.: Myocardial Ischaemia Reduction with Aggresive Cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J. Am. Med. Assoc., 2001, 285, 1711-1718.
• 54. Shepherd J., et al.: For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 1995, 333, 1301-1307.
• 55. Stein E.: Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur. Heart J., 2001, 3(suppl. E), E-ll-E-16.
• 56. Stenestrand U., Vallentin L.: for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. J. Am. Med. Assoc., 2001, 285, 430-436.
• 57. Szostak W.B., i wsp.: HDL-chol, apo B, total cholesterol (TC) and triglycerides (TG) in umbilical cord blood. Żyw. Czlow. Metab., 1984, 11, 231-236.
• 58. Takemoto M., Liao J. K.: Pleiotropic effects of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vase. Biol., 2001, 21, 1712-1719.
• 59. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. N. Engl. J. Med., 2000, 324, 154- 160.
• 60. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002, 106, 3145- 3420.-
• 61. Thompson G.R.: A. handbook of hyperlipidaemia. Current Science, Second Edition, 1994.
• 62. Thompson PL., et al.: on behalf of the PACT Investigators Presented at the World Congress of Cardiology. May 2002, Sydney.
• 63. Ucar M., Mjorndal T., Dahlquist R.: HMG-CoA reductase inhibitors and myotoxicity. Drug Safety, 2000, 22, 441-457.
• 64. Westrate J.A., Meijer G.W.: Plant sterol-enriched margarines and reduction of plasma total - and LDL cholesterol concentrations in normo- cholesterolaemic and mildy hypercholesterolaemic subjects. Eur. J. Clin. Nutr., 1998, 52, 334-343.